Docket No.: 19603/4071 (CR

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFI

Vivian E. Mack Strong et al. 09/782,936

Cnfrm. No. 1665

Applicants

Serial No.

Art Unit:

Filed February 14, 2001 1614

For

USE OF COX-2 INHIBITORS TO TREAT SEPSIS, COMPLICATIONS THEREOF, AND EP RECEPTOR MODULATION

U.S. Patent and Trademark Office

P.O. Box 2327

Arlington, VA 22202

Sir:

Transmitted herewith is an amendment (6 pages) and Appendix (1 page) in the above-identified application. Also enclosed are:

- A Request for Three-Month Extension of Time. [X]
- Applicant claims small entity status. (See 37 CFR 1.27.) [X]
- A self-addressed, prepaid postcard for acknowledging receipt. [X]
- No additional fee is required. []
- [X]The fee has been calculated as shown below:

a) SMALL ENTITY

b) LARGE ENTITY (Col. 2) (Col. 3) (Col. 1)

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADD'L FEE
TOTAL	6	MINUS	24	+ >	a) \$ 9= b) \$18	\$0
INDEP	1	MINUS	5	+ >	a) \$42= b) \$84	\$0
, ,					See fee Schedule	\$465.00
					TOTAL	\$465.00

A check for \$465.00 is enclosed to cover the above fees.

[]	Please charge my Deposit Account No. 14-1138 in the amount of \$ A duplicate copy of this sheet is enclosed.
[X]	The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 14-1138.

A duplicate copy of this sheet is enclosed.

March 7,2003

Michael L. Goldman Registration No. 30,727

NIXON PEABODY LLP Clinton Square, P.O. Box 31051

[X]

Date:

Rochester, New York 14603-1051 Telephone: (585) 263-1304 Facsimile: (585) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
U.S Patent and Trademark Office P.O. BOX 2327
Arlington, VA 22202, on the date below.

Cheryl S. Mascitti



Docket No.: 19603/4071 (CRFQ 25984)

Examiner:

William R. Jarvis

Art Unit: 1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Vivian E. Mack Strong et al.

Serial No.

09/782,936

Cnfrm. No.

1665

Filed

February 14, 2001

For

USE OF COX-2 INHIBITORS TO TREAT SEPSIS, COMPLICATIONS THEREOF,

AND EP RECEPTOR MODULATION

AMENDMENT

U.S. Patent and Trademark Office

P.O. Box 2327

Arlington, VA 22202

Dear Sir:

In response to the September 10, 2002, office action, please amend the aboveidentified application as follows:

In the Claims:

Please cancel claims 2-14 and 16-23.

Please add new claims 24-27 as follows:

- 24. The method according to claim 1, wherein the patient at risk for systemic inflammatory response syndrome and complications thereof is a patient who has sustained trauma.
- 25. The method according to claim 1, wherein the patient at risk for systemic inflammatory response syndrome and complications thereof is a patient who has sustained life threatening blood loss from penetrating injury.